In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation

References

• Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75(4):1024–1030.
   PubMed Web of Science ®Google Scholar
• Martelli MF, Aversa F. Haploidentical transplants using ex vivo T-cell depletion. Semin Hematol. 2016;53(4):252–256.
   PubMed Web of Science ®Google Scholar
• Bayraktar UD, Champlin RE, Ciurea SO. Progress in haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:372–380.
   PubMed Web of Science ®Google Scholar
• Airoldi I, Bertaina A, Prigione I, et al. γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-ab1/CD191 lymphocytes. Blood. 2015;125(15):2349–2358.
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121–3127.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–955.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100(2):415–419.
   PubMed Web of Science ®Google Scholar
• Flowers MED, Martin PJ. How I treat chronic graft-versus-host disease. Blood. 2015;125:606–615.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389–401.
   PubMed Web of Science ®Google Scholar
• Ferrara JLM, Deeg HJ. Graft-versus-host disease. New Engl J Med. 1991;324:667–674.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant. 2005;35(3):225–231.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Antithymocyte globulin for prevention of graft versus-host disease. Curr Opin Hematol. 2005;12(6):457–462.
   PubMed Web of Science ®Google Scholar
• Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387–1394.
   PubMed Web of Science ®Google Scholar
• Popow I, Leitner J, Majdic O, et al. Assessment of batch to batch variation in polyclonal antithymocyte globulin preparations. Transplantation. 2012;93(1):32–40.
   PubMed Web of Science ®Google Scholar
• Pistillo MA, Tazzari PL, Bonifazi F, et al. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. Transplantation. 2002;73:1295–1302.
   PubMed Web of Science ®Google Scholar
• Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008;111(7):3675–3683.
   PubMed Web of Science ®Google Scholar
• Waller EK, Langston AA, Lonial S, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2003;9:460–471.
   PubMed Web of Science ®Google Scholar
• Remberger M, Sundberg B. Low serum levels of total rabbit-IgG Is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant. 2009;15:996–999.
   PubMed Web of Science ®Google Scholar
• Huang W, Zhao X, Tian Y, et al. Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study. Med Oncol. 2015;32:32–40.
   Web of Science ®Google Scholar
• Huang W, Yu L, Cao T, et al. The efficacy and safety of rabbit anti-thymocyte globulin vs rabbit anti-T-lymphocyte globulin in peripheral blood stem cell transplantation from unrelated donors. Leuk Lymphoma. 2016;57:355–363.
   PubMed Web of Science ®Google Scholar
• Paiano S, Roosnek E, Tirefort Y, et al. comparing two types of rabbit ATG prior to reduced intensity conditioning allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Res. 2015;2015:1–7.
   Web of Science ®Google Scholar
• Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant. 2005;35:1011–1018.
   PubMed Web of Science ®Google Scholar
• Imataki O, Matsumoto K, Uemura M. Low-dose anti-thymocyte globulin reduce severe acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. J Cancer Res Clin Oncol. 2017;143:709–715.
   PubMed Web of Science ®Google Scholar
• Duléry R, Mohty M, Duhamel A, et al. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2014;20:646–654.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Gualandi F, et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant. 2002;8:656–661.
   PubMed Web of Science ®Google Scholar
• Remberger M, Storer B, Ringden O, et al. Post-transplant complications association between pretransplant Thymoglobulin and reduced nonrelapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant. 2002;29:391–397.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98:2942–2947.
   PubMed Web of Science ®Google Scholar
• Mohty M, Labopin M, Balere ML, et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia. 2010;24:1867–1874.
   PubMed Web of Science ®Google Scholar
• Langston AA, Prichard JM, Muppidi S, et al. Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors. Bone Marrow Transplant. 2014;49:185–189.
   PubMed Web of Science ®Google Scholar
• Kuriyama K, Fuji S, Inamoto Y, et al. Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. Int J Hematol. 2016;103:453–460.
   PubMed Web of Science ®Google Scholar
• Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17:164–173.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Parody R, Perkins J, et al. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52:438–444.
   PubMed Web of Science ®Google Scholar
• Russell JA, Turner A, Larratt L, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant. 2007;13:299–306.
   PubMed Web of Science ®Google Scholar
• Bredeson CN, Zhang M-J, Agovi M-A, et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:993–1003.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Deol V, Ayash L, et al. Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant. 2015;50:106–112.
   PubMed Web of Science ®Google Scholar
• Rubio MT, D’Aveni-Piney M, Labopin M, et al. Impact of in vivo T cell depletion in HLA identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT acute leukemia working party. J Hematol Oncol. 2017;10:31.
   PubMed Web of Science ®Google Scholar
• Kroger N, Zabelina T, Kruger W, et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant. 2002;29:683–689.
   PubMed Web of Science ®Google Scholar
• Bonifazi F, Bandini G, Arpinati M, et al. Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis. Bone Marrow Transplant. 2012;47:1105–1111.
   PubMed Web of Science ®Google Scholar
• Wolschke C, Zabelina T, Ayuk F, et al. Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or - mismatched sibling peripheral blood stem cell transplantation. Bone Marrow Transplant. 2014;49:126–130.
   PubMed Web of Science ®Google Scholar
• Binkert L, Medinger M, Halter JP, et al. Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015;50:1331–1336.
   PubMed Web of Science ®Google Scholar
• Kroger N, Solano C, Wolschke C, et al. Antithymocyte globulin for prevention of chronic graft-versus-host disease. New Engl J Med. 2016;374:43–53.
   PubMed Web of Science ®Google Scholar
• Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–864.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graftversus- host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12:573–584.
   PubMed Web of Science ®Google Scholar
• Ayuk F, Diyachenko G, Zabelina T, et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:913–919.
   PubMed Web of Science ®Google Scholar
• Devillier R, Crocchiolo R, Castagna L, et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant. 2012;47:639–645.
   PubMed Web of Science ®Google Scholar
• Hatanaka K, Fuji S, Ikegame K, et al. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin. Int J Hematol. 2012;96:773–780.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Esterni B, Castagna L, et al. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer. 2013;119:986–992.
   PubMed Web of Science ®Google Scholar
• Cornillon J, Balsat M, Cabrespine A, et al. Impact of ATG dose on the outcome of patients undergoing reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation for hematological malignancies. Acta Haematol. 2016;136:193–200.
   PubMed Web of Science ®Google Scholar
• Bonifazi F, Bandini G, Rondelli D, et al. Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML. Bone Marrow Transplant. 2003;32:237–242.
   PubMed Web of Science ®Google Scholar
• Fuji S, Kim S-W, Yano S, et al. A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F. Bone Marrow Transplant. 2016;51:451–453.
   PubMed Web of Science ®Google Scholar
• Finke J, Schmoor C, Bethge WA, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017;4:e293–301.
   PubMed Web of Science ®Google Scholar
• Baron F, Labopin M, Blaise D, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49:389–396.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, LeRademacher J, Ho V, et al. Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117:6963–6970.
   PubMed Web of Science ®Google Scholar
• Lu D-P, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–3073.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu D-H, Liu K-Y, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia nine years of experience at a single center. Cancer. 2013;119:978–985.
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo P, Santarone S, De Angelis G, et al. unmanipulated, G-CSF–primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood. 2013;121:849–857.
   PubMed Web of Science ®Google Scholar
• Bonifazi F, Bandini G, Stanzani M, et al. In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. Bone Marrow Transplant. 2005;35:1025–1026.
   PubMed Web of Science ®Google Scholar
• Admiraal R, Nierkens S, de Witte MA, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017;4:e183–91.
   PubMed Web of Science ®Google Scholar
• Kumar A, Mhaskar AR, Reljic T, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012;26:582–588.
   PubMed Web of Science ®Google Scholar
• Du K, Hu Y, Wu K, et al. Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Clin Transplant. 2013;27:E91–E100.
   PubMed Web of Science ®Google Scholar
• Arai Y, Jo T, Matsui H, et al. Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma. 2016. DOI:10.1080/10428194.2016
   Google Scholar
• Yuan J, Pei R, Su W, et al. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation. Oncotarget. 2017;8:10871–10882.
   Web of Science ®Google Scholar
• Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120–2130.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Hansen JA, Torok-Storb B, et al. Graft failure in patients receiving T-cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant. 1988;3:445–456.
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Carotti A, et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol. 1999;17(5):1545–1550.
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;7:555–562.
   Google Scholar
• Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet. 1981;2:327–331.
   PubMed Web of Science ®Google Scholar
• Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61:341–348.
   PubMed Web of Science ®Google Scholar
• O’Reilly RJ, Brochstein J, Collins N, et al. Evaluation of HLA-haplotype disparate parental marrow grafts depleted of T lymphocytes by differential agglutination with a soybean lectin and E-rosette depletion for the treatment of severe combined immunodeficiency. Vox Sanguinis. 1986;51:81–86.
   PubMed Web of Science ®Google Scholar
• Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. New Eng J Med. 2014;371:434–446.
   PubMed Web of Science ®Google Scholar
• Gale RP. Reisner Y. Graft rejection and graft versus host disease: a mirror image. Lancet. 1986;1:1468–1470.
   PubMed Web of Science ®Google Scholar
• Reisner Y, Ben-Bassat I, Dourer D, et al. Demonstration of clonable alloreactive host cells in a primate model for bone marrow transplantation. Proc Natl Acad Sci USA. 1986;83:4012–4015.
   PubMed Web of Science ®Google Scholar
• Terenzi A, Aversa F, Albi N, et al. Residual clonable host cell detection for predicting engraftment of T cell depleted BMTs. Bone Marrow Transplant. 1993;11:357–361.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Terenzi A, Singer TS, et al. Enhancement by dimethyl myleran of donor type chimerism in murine recipient of bone marrow allografts. Blood. 1989;73:2025–2032.
   PubMed Web of Science ®Google Scholar
• Terenzi A, Lubin I, Lapidot T, et al. Enhancement of T-cell-depleted bone marrow allografts in mice by thiotepa. Transplantation. 1990;50:717–720.
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998;91:1083–1090.
   PubMed Web of Science ®Google Scholar
• Jakubowski AA, Small TN, Young JW, et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007;110:4552–4559.
   PubMed Web of Science ®Google Scholar
• Bayraktar UD, de Lima M, Saliba RM, et al. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013;19(6):898–903.
   PubMed Web of Science ®Google Scholar
• Devine SM, Carter S, Soiffer RJ, et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011;17(9):1343–1351.
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Devine S, Mendizabal AM, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol. 2012;30:3194–3201.
   PubMed Web of Science ®Google Scholar
• de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–864.
   PubMed Web of Science ®Google Scholar
• Boulad F, Jakubowski A, Papadopoulos EB, et al. Phase II trial of a chemotherapy-only regimen of busulfan, melphalan, fludarabine and R-ATG followed by allogeneic T-cell depleted hematopoietic stem cell transplants for the treatment of myeloid malignancies. Blood. 2007;110:2991a.
   Google Scholar
• Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today. 1995;16:437–440.
   PubMedGoogle Scholar
• Rachamin N, Gan J, Segall H, et al. Tolerance induction by “megadose” hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation. 1998;65:1386–1393.
   PubMed Web of Science ®Google Scholar
• Bachar-Lusting E, Rachamim N, Li HW, et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nature Med. 1995;1:1268–1273.
   PubMed Web of Science ®Google Scholar
• Gur H, Krauthgamer R, Berrebi A, et al. Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood. 2002;99:4174–4181.
   PubMed Web of Science ®Google Scholar
• Gur H, Krauthgamer R, Bachar-Lustig E, et al. Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-alpha. Blood. 2005;105(6):2585–2593.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84:3948–3955.
   PubMed Web of Science ®Google Scholar
• Terenzi A, Aristei C, Aversa F, et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc. 1996;28:3101.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of high risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–1193.
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Tabilio A, et al. Full-haplotype mismatched hematopoietic stem cell transplantation: a phase II study in patients with acute leukemia at high risk or relapse. J Clin Oncol. 2005;23:3447–3454.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110(1):433–440.
   PubMed Web of Science ®Google Scholar
• Velardi A, Ruggeri L, Mancusi A, et al. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol. 2009;21(5):525–530.
   PubMed Web of Science ®Google Scholar
• Aversa F, Martelli MF, Velardi A. Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity. Semin Oncol. 2012;39(6):643–652.
   PubMed Web of Science ®Google Scholar
• Stern M, Ruggeri L, Mancusi A, et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood. 2008;112:2990–2995.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pende D, Maccario R, et al. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol. 2009;133:171–178.
   PubMed Web of Science ®Google Scholar
• Moretta L, Locatelli F, Pende D, et al. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011;117:764–771.
   PubMed Web of Science ®Google Scholar
• Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112:3574–3581.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34+ progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001;27:777–783.
   PubMed Web of Science ®Google Scholar
• Lang P, Greil J, Bader P, et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis. 2004;33:281–287.
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Cornish J, Labopin M, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size. An analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group. Blood. 2010;115:3437–3446.
   PubMed Web of Science ®Google Scholar
• Sairafi D, Mattsson J, Uhlin M, et al. Thymic function after allogeneic stem cell transplantation is dependent on graft source and predictive of long term survival. Clin Immunol. 2012;142(3):343–350.
   PubMed Web of Science ®Google Scholar
• Marek A, Stern M, Chalandon Y, et al. Swiss Blood Stem Cell Transplantation. The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. Bone Marrow Transplant. 2014;49(1):55–61.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Schwarck S, Stroux A, et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol. 2010;91(5):877–885.
   PubMed Web of Science ®Google Scholar
• Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397–4406.
   PubMed Web of Science ®Google Scholar
• Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114(19):4283–4292.
   PubMed Web of Science ®Google Scholar
• Comoli P, Schilham MW, Basso S, et al. T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors. J Immunother. 2008;31(6):529–536.
   PubMed Web of Science ®Google Scholar
• Perruccio K, Topini F, Tosti A, et al. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2008;40(1):76–83.
   PubMed Web of Science ®Google Scholar
• Ciceri F, Bonini C, Stanghellini MTL, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009;10(5):489–500.
   PubMed Web of Science ®Google Scholar
• Vago L, Oliveira G, Bondanza A. T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood. 2012;120(9):1820–1830.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Del Papa B, Cecchini D, et al. Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications. Clin Exp Immunol. 2009;156(2):246–253.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921–3928.
   PubMed Web of Science ®Google Scholar
• Martelli MF, Di Ianni M, Ruggeri L, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124(4):638–644.
   PubMed Web of Science ®Google Scholar
• Bader P, Soerensen J, Jarisch A, et al. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19 depleted stem cells. Best Pract Res Clin Haematol. 2011;24(3):331–337.
   PubMed Web of Science ®Google Scholar
• Handgretinger R. New approaches to graft engineering for haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):664–673.
   PubMed Web of Science ®Google Scholar
• Carding SR, Egan PJ. Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol. 2002;2(5):336–345.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Bauquet A, Palumbo G, et al. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol Lett. 2013;155(1–2):21–23.
   PubMed Web of Science ®Google Scholar
• Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood. 2014 Jul 31;124(5):822–826.
   PubMed Web of Science ®Google Scholar
• Al Malki MM, Horowitz M, Handgretinger R, et al. Proceedings from the second haploidentical stem cell transplantation symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016;22(4):594–604.
   PubMed Web of Science ®Google Scholar
• Perko R, Kang G, Sunkara A, et al. Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia. Biol Blood Marrow Transplant. 2015;21(1):130–136.
   PubMed Web of Science ®Google Scholar
• Ismail AS, Behrendt CL, Hooper LV. Reciprocal interactions between commensal bacteria and gammadelta intraepithelial lymphocytes during mucosal injury. J Immunol. 2009;182:3047–3054.
   PubMed Web of Science ®Google Scholar
• Prezioso L, Monti A, Manfra I, et al. T αβ/CD19 depletion in haploidentical transplantation prevents GVHD and allows a prompt and effective immune reconstitution in adult patients with acute leukemia. EBMT meeting. Marseil;Springer Nature. 2017. (abstract).
   Google Scholar
• Kaynar L, Demir K, Turak EE, et al. TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients. Hematology. 2017 Apr;22(3):136–144.
   PubMed Web of Science ®Google Scholar